CXCR3 and neoplasm: The tumor volume and weight in immunodeficient animals treated with AMG487 were statistically significantly lower than in control animals (p = 0.001 and 0.008, Student’s t-test, respectively; Figure 6B–E), supporting the conclusion that the antagonist of CXCR3 inhibits the tumor growth in an immunodeficient model.